Early health technology assessment during nonalcoholic steatohepatitis drug development: a two-round, cross-country, multicriteria decision analysis

Angelis, Aris ORCID: 0000-0002-0261-4634, Thursz, Mark, Ratziu, Vlad, O'Brien, Alistair, Serfaty, Lawrence, Canbay, Ali, Schiefke, Ingolf, Bana e Costa, João C., Lecomte, Pascal and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2020) Early health technology assessment during nonalcoholic steatohepatitis drug development: a two-round, cross-country, multicriteria decision analysis. Medical Decision Making, 40 (6). 830 - 845. ISSN 0272-989X

	Text (Early health technology assessment during non-alcoholic steatohepatitis (NASH) drug development) - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB)
	Text (Appendix_20JUL_online_supp 2) Available under License Creative Commons Attribution Non-commercial. Download (1MB)

• Author
• Author

Abstract

Background. The assessment of value along the clinical development of new biopharmaceutical compounds is a challenging task. Complex and uncertain evidence has to be analyzed, considering a multitude of value preferences from different stakeholders. Objective. To investigate the use of multicriteria decision analysis (MCDA) to support decision making during drug development while considering payer and health technology assessment (HTA) value concerns, by applying the Advance Value Framework in nonalcoholic steatohepatitis (NASH) and testing for the consistency of the results. Design. A multiattribute value theory methodology was applied and 2 rounds of decision conferences (DCs) were organized in 3 countries (England, France, and Germany), with the participation of national key experts and stakeholders using the MACBETH questioning protocol and algorithm. A total of 51 health care professionals, patient advocates, and methodologists, including (ex-) committee members or assessors from national HTA bodies, participated in 6 DCs in the study countries. Target Population. NASH patients in fibrosis stages F2 to 3 were considered. Interventions. The value of a hypothetical product profile was assessed against 3 compounds under development using their phase 2 results. Outcome Measures. DC participants’ value preferences were elicited involving criteria selection, options scoring, and criteria weighting. Results. Highly consistent valuation rankings were observed in all DCs, always favoring the same compound. Highly consistent rankings of criteria clusters were observed, favoring therapeutic benefit criteria, followed by safety profile and innovation level criteria. Limitations. There was a lack of comparative treatment effects, early evidence on surrogate endpoints was used, and stakeholder representativeness was limited in some DCs. Conclusions. The use of MCDA is promising in supporting early HTA, illustrating high consistency in results across countries and between study rounds.

Item Type:	Article
Official URL:	https://journals.sagepub.com/home/mdm
Additional Information:	© 2022 The Authors CC-BY-NC
Divisions:	LSE Health Health Policy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	23 Jun 2020 10:51
Last Modified:	01 Nov 2024 05:35
URI:	http://eprints.lse.ac.uk/id/eprint/105167

Actions (login required)

View Item